利用化疗特征图谱追踪治疗相关髓系肿瘤的演化
研究利用全基因组测序的化疗相关突变特征和化疗前样本靶向测序,重建了39例治疗相关髓系恶性肿瘤的演化史。发现两类:铂类和美法仑诱导突变者呈超突变并富集复杂结构变异,非诱变化疗者基因组类似原发急性髓系白血病。部分患者tMN可不依赖直接诱变或化疗暴露而进展。
要点
- 化疗相关突变特征可作为时间条形码,追溯tMN中复杂事件和驱动突变的获得时序。
- 铂类和美法仑诱导突变的tMN呈超突变并富集复杂结构变异(如染色体碎裂)。
- 多发性骨髓瘤患者tMN可源于回输的克隆性造血克隆或存活于清髓预处理并获美法仑DNA损伤的TP53突变克隆。
核心结论
- 研究揭示了tMN的一种不依赖直接诱变或化疗暴露的新进展模式。
- 在化疗诱导突变影响下演化的tMN中,不同化疗不仅选择既存克隆性造血,还促进复发性基因组驱动事件的获得。
研究设计与样本
- 利用全基因组测序数据的化疗相关突变特征和化疗前样本靶向测序,重建39例治疗相关髓系恶性肿瘤的演化史。
主要发现
- 有铂类和美法仑诱导突变证据的肿瘤呈超突变并富集复杂结构变异(即染色体碎裂)。
- 非诱变化疗暴露的肿瘤基因组与原发急性髓系白血病相似。
- 估计若干复杂事件和基因组驱动在化疗给药后获得。
- 接受大剂量美法仑和自体干细胞移植的多发性骨髓瘤患者中,tMN可源于逃避美法仑暴露并在回输后被选择的回输克隆性造血克隆,或源于存活直接清髓预处理并获得美法仑诱导DNA损伤的TP53突变克隆性造血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Preleukemic clones (ie, clonal hematopoiesis [CH]) are detectable years before the development of these aggressive malignancies, although the genomic events leading to transformation and expansion are not well defined. Here, by leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted sequencing of prechemotherapy samples, we reconstructed the evolutionary life-history of 39 therapy-related myeloid malignancies. A dichotomy was revealed, in which neoplasms with evidence of chemotherapy-induced mutagenesis from platinum and melphalan were hypermutated and enriched for complex structural variants (ie, chromothripsis), whereas neoplasms with nonmutagenic chemotherapy exposures were genomically similar to de novo acute myeloid leukemia. Using chemotherapy-associated mutational signatures as temporal barcodes linked to discrete clinical exposure in each patient's life, we estimated that several complex events and genomic drivers were acquired after chemotherapy was administered. For patients with prior multiple myeloma who were treated with high-dose melphalan and autologous stem cell transplantation, we demonstrate that tMN can develop from either a reinfused CH clone that escapes melphalan exposure and is selected after reinfusion, or from TP53-mutant CH that survives direct myeloablative conditioning and acquires melphalan-induced DNA damage. Overall, we revealed a novel mode of tMN progression that is not reliant on direct mutagenesis or even exposure to chemotherapy. Conversely, for tMN that evolve under the influence of chemotherapy-induced mutagenesis, distinct chemotherapies not only select preexisting CH but also promote the acquisition of recurrent genomic drivers.
引用
- Diamond B, Ziccheddu B, Maclachlan K, et al. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023. PMID: 36626250. doi:10.1182/blood.2022018244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。